| (Values in U.S. Thousands) | Sep, 2021 | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 |
| Sales | 6,340 | 9,170 | 6,610 | 10,870 | 5,510 |
| Sales Growth | -30.86% | +38.73% | -39.19% | +97.28% | -48.12% |
| Net Income | -6,840 | -3,970 | -6,380 | -2,420 | -6,430 |
| Net Income Growth | -72.29% | +37.77% | -163.64% | +62.36% | -968.92% |
Biofrontera Ag ADR (BFRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company's products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany.